AstraZeneca plc (NYSE:AZN) – Stock analysts at Jefferies Group raised their FY2017 earnings per share (EPS) estimates for AstraZeneca in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will post earnings of $1.88 per share for the year, up from their prior estimate of $1.85.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business earned $1.32 earnings per share. The business’s quarterly revenue was up 9.4% compared to the same quarter last year.

Several other equities research analysts have also issued reports on AZN. BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday, January 10th. Cowen reissued a “hold” rating and issued a $37.00 price objective on shares of AstraZeneca in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Finally, BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $34.20.

Shares of AstraZeneca (NYSE AZN) opened at $35.08 on Thursday. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.92. The stock has a market cap of $88,610.15, a price-to-earnings ratio of 12.57, a PEG ratio of 3.42 and a beta of 0.72. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fisher Asset Management LLC grew its holdings in AstraZeneca by 4.7% during the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares in the last quarter. Wells Fargo & Company MN grew its holdings in AstraZeneca by 7.6% during the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in AstraZeneca by 7.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares in the last quarter. Capital Bank & Trust Co grew its holdings in AstraZeneca by 2.1% during the 3rd quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in AstraZeneca by 18.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after purchasing an additional 395,699 shares in the last quarter. 14.75% of the stock is owned by institutional investors and hedge funds.

WARNING: “Analysts Issue Forecasts for AstraZeneca plc’s FY2017 Earnings (AZN)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/18/analysts-issue-forecasts-for-astrazeneca-plcs-fy2017-earnings-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Earnings History and Estimates for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.